The global alpha-synuclein market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Alpha-synuclein is a neuronal protein that is encoded by the SNCA gene in humans and is abundant in the brain, while smaller amounts of it are found in the heart, muscle, and other tissues. Alpha-synuclein is a protein that regulates synaptic vesicle trafficking and subsequent neurotransmitter release. Abnormal alpha-synuclein depositions (?-synucleinopathies) in neurons, nerve fibers, or glia cells are the causes for several neurodegenerative diseases such as Parkinson’s disease, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Parkinson’s disease is the most common progressive neurodegenerative movement disorder with significant prevalence and incidences across the globe. 

Increasing prevalence and incidences of Parkinson’s disease globally is one of the major factors that is augmenting the growth of the global alpha-synuclein market. A significant increase in the number of Parkinson’s disease patients along with the limited treatment solutions for this disease serves as a potential growth factor for the market globally. Furthermore, industry players are aggressively focusing on the development of treatment solutions for Parkinson’s disease through alpha-synuclein which is further boosting the market growth. For instance, Roche presented its monoclonal antibody (mAb)-targeting alpha (?)-synuclein, prasinezumab, for the treatment of Parkinson’s disease at the 15th International Virtual Conference on Alzheimer’s disease and Parkinson’s disease (AD/PD) 2021. Prasinezumab is an ?-synuclein mAb administered intravenously as an infusion.

Some key players operating in the market include F. Hoffmann La-Roche AG, and H. Lundbeck A/S, among others. These players are eyeing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships and collaborations, new product launches, development in the existing product portfolio, and so on.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application 

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  F. Hoffmann La-Roche AG, and H. Lundbeck A/S, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Alpha Synuclein Market Report by Segment

By Type

• AV-1950R
• AV-1947D
• BAN-0805
• BIIB-054
• DPC-003
• Others

By Application

• Multiple System Atrophy
• Neurodegenerative Disease
• Lewy Body Dementia
• Others

Global Alpha Synuclein Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa